{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T11:51:15Z","timestamp":1790941875947,"version":"4.1.0"},"reference-count":81,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:p>Clopidogrel is the most widely used P2Y12 receptor inhibitor (P2Y12i) as a part of dual antiplatelet therapy along with aspirin. Clopidogrel is a pro-drug and is metabolized to its active metabolite by the hepatic enzyme cytochrome P4502C19 (CYP2C19). This active metabolite is responsible for the antiplatelet action of clopidogrel. Recent studies have demonstrated that single nucleotide polymorphisms in the CYP2C19 gene, including CYP2C19*2,*3,*4, and *5 alleles, result in reduced production of the active metabolite of clopidogrel, and hence reduced inhibition of platelet aggregation. This in turn enhances the incidence of stent thrombosis and recurrent cardiovascular (CV) events. We report a case of coronary stent thrombosis due to clopidogrel resistance proven by CYP2C19 genotyping. We then review the literature on clopidogrel resistance and its impact on CV outcomes. Subsequently, we discuss the methods of diagnosis of resistance, evidence from clinical trials for tailoring clopidogrel therapy, the role of potent P2Y12 inhibitors, the current guidelines, and future directions.<\/jats:p>","DOI":"10.4103\/jfmpc.jfmpc_1473_23","type":"journal-article","created":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T06:04:51Z","timestamp":1718345091000},"page":"2187-2199","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["Clopidogrel resistance and its relevance: Current concepts"],"prefix":"10.4103","volume":"13","author":[{"given":"Akshyaya","family":"Pradhan","sequence":"first","affiliation":[{"name":"Department of Cardiology, King George\u2019s Medical University, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Bhandari","sequence":"additional","affiliation":[{"name":"Department of Cardiology, King George\u2019s Medical University, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pravesh","family":"Vishwakarma","sequence":"additional","affiliation":[{"name":"Department of Cardiology, King George\u2019s Medical University, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi","family":"Sethi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, King George\u2019s Medical University, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,6,14]]},"reference":[{"key":"R1-20260204","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/01.CIR.102.6.624","article-title":"Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: The clopidogrel aspirin stent international cooperative study (CLASSICS)","volume":"102","author":"Bertrand","year":"2000","journal-title":"Circulation"},{"key":"R2-20260204","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"key":"R3-20260204","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/0006-2952(92)90445-O","article-title":"Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel","volume":"44","author":"Savi","year":"1992","journal-title":"Biochem Pharmacol"},{"key":"R4-20260204","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome P-450 polymorphisms and response to clopidogrel","volume":"360","author":"Mega","year":"2009","journal-title":"N Engl J Med"},{"key":"R5-20260204","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1016\/S0735-1097(01)01285-2","article-title":"Incidence of thrombotic occlusion and major adverse cardiac events between two and four weeks after coronary stent placement: Analysis of 5,678 patients with a four-week ticlopidine regimen","volume":"37","author":"Schuhlen","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"R6-20260204","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.jacc.2007.10.057","article-title":"Drug-eluting stent thrombosis: Results from the multicenter Spanish registry ESTROFA (Estudio ESpanol sobre TROmbosis de stents FArmacoactivos)","volume":"51","author":"De la Torre-Hernandez","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"R7-20260204","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1161\/CIRCULATIONAHA.105.600155","article-title":"Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents","volume":"113","author":"Kuchulakanti","year":"2006","journal-title":"Circulation"},{"key":"R8-20260204","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4070\/kcj.2005.35.2.163","article-title":"Stent thrombosis after successful drug-eluting stent implantation","volume":"35","author":"Park","year":"2005","journal-title":"Korean Circ J"},{"key":"R9-20260204","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0002-9149(01)01631-9","article-title":"Profile and prevalence of aspirin resistance in patients with cardiovascular disease","volume":"88","author":"Gum","year":"2001","journal-title":"Am J Cardiol"},{"key":"R10-20260204","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1161\/01.CIR.0000072771.11429.83","article-title":"Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity","volume":"107","author":"Gurbel","year":"2003","journal-title":"Circulation"},{"key":"R11-20260204","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1161\/01.CIR.0000134701.40946.30","article-title":"Clopidogrel resistance: A new chapter in a fast-moving story","volume":"109","author":"Wiviott","year":"2004","journal-title":"Circulation"},{"key":"R12-20260204","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1182\/blood-2006-04-013052","article-title":"Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects","volume":"108","author":"Hulot","year":"2006","journal-title":"Blood"},{"key":"R13-20260204","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1111\/j.1538-7836.2008.03050.x","article-title":"The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects","volume":"6","author":"Umemura","year":"2008","journal-title":"J Thrombosis Haemostasis"},{"key":"R14-20260204","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2165\/00003088-200241120-00002","article-title":"Clinical significance of the cytochrome P450 2C19 genetic polymorphism","volume":"41","author":"Desta","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"R16-20260204","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ihj.2013.10.001","article-title":"CYP 450 2C19 polymorphisms in Indian patients with coronary artery disease","volume":"66","author":"Shetkar","year":"2014","journal-title":"Indian Heart J"},{"key":"R17-20260204","first-page":"BC17","article-title":"Frequency of CYP2C19*2 Allele in patients with acute coronary syndrome: A cross-sectional study from Central Kerala, India","volume":"15","author":"George","year":"2021","journal-title":"J Clin Diagn Res"},{"key":"R18-20260204","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1111\/j.1538-7836.2007.02775.x","article-title":"Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel","volume":"5","author":"Brandt","year":"2007","journal-title":"J Thromb Haemost"},{"key":"R19-20260204","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jcin.2011.03.002","article-title":"High doses of clopidogrel to overcome genetic resistance: The randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2)","volume":"4","author":"Collet","year":"2011","journal-title":"JACC Cardiovasc Interv"},{"key":"R20-20260204","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1016\/j.jacc.2007.07.058","article-title":"Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes","volume":"50","author":"Storey","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"R21-20260204","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"R22-20260204","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/jama.2011.290","article-title":"Standard vs high dose clopidogrel based on platelet function testing after percutaneous coronary intervention: The GRAVITAS randomized trial","volume":"305","author":"Price","year":"2011","journal-title":"JAMA"},{"key":"R23-20260204","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1161\/CIRCULATIONAHA.111.029165","article-title":"Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: A time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial","volume":"124","author":"Price","year":"2011","journal-title":"Circulation"},{"key":"R24-20260204","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.jacc.2012.02.026","article-title":"A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: Results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study","volume":"59","author":"Trenk","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"R25-20260204","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1056\/NEJMoa1209979","article-title":"Bedside monitoring to adjust antiplatelet therapy for coronary stenting","volume":"367","author":"Collet","year":"2012","journal-title":"N Engl J Med"},{"key":"R26-20260204","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1161\/CIRCULATIONAHA.113.007524","article-title":"High on-treatment platelet reactivity as a risk factor for secondary prevention after coronary stent revascularization: A landmark analysis of the ARCTIC study","volume":"129","author":"Montalescot","year":"2014","journal-title":"Circulation"},{"key":"R27-20260204","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(16)31323-X","article-title":"Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): An open-label, blinded end point, randomised controlled superiority trial","volume":"388","author":"Cayla","year":"2016","journal-title":"Lancet"},{"key":"R28-20260204","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(12)60161-5","article-title":"Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): A prospective, randomised, proof-of-concept trial","volume":"379","author":"Roberts","year":"2012","journal-title":"Lancet"},{"key":"R29-20260204","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.jacc.2018.02.029","article-title":"Pharmacogenomic approach to selecting antiplatelet therapy in patients with acute coronary syndromes: The PHARMCLO trial","volume":"71","author":"Notarangelo","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"R30-20260204","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1907096","article-title":"A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI","volume":"381","author":"Claassens","year":"2019","journal-title":"N Engl J Med"},{"key":"R31-20260204","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s00228-019-02696-z","article-title":"Tailored P2Y12 inhibitor treatment in patients undergoing non-urgent PCI\u2014the POPular Risk Score study","volume":"75","author":"Janssen","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"key":"R32-20260204","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.2020.12443","article-title":"Effect of Genotype- Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial","volume":"324","author":"Pereira","year":"2020","journal-title":"JAMA"},{"key":"R33-20260204","doi-asserted-by":"crossref","first-page":"e002640","DOI":"10.1161\/CIRCGEN.119.002640","article-title":"Prospective CYP2C19 genotyping to guide antiplatelet therapy following percutaneous coronary intervention: A pragmatic randomized clinical trial","volume":"13","author":"Tuteja","year":"2020","journal-title":"Circ Genom Precis Med"},{"key":"R34-20260204","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/eurheartj\/eht375","article-title":"Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention","volume":"35","author":"Aradi","year":"2014","journal-title":"Eur Heart J"},{"key":"R35-20260204","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.jcin.2019.03.034","article-title":"Updated expert consensus statement on platelet function and genetic testing for guiding P2Y12 receptor inhibitor treatment in percutaneous coronary intervention","volume":"12","author":"Sibbing","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"key":"R36-20260204","first-page":"841","article-title":"Clopidogrel non responsiveness and risk of cardiovascular morbidity. An updated meta-analysis","volume":"103","author":"Sofi","year":"2010","journal-title":"Thromb Haemost"},{"key":"R37-20260204","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/j.jacc.2011.06.059","article-title":"Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data","volume":"58","author":"Brar","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"R38-20260204","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/eurheartj\/ehv104","article-title":"Bleeding and stent thrombosis on P2Y12-inhibitors: Collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention","volume":"36","author":"Aradi","year":"2015","journal-title":"Eur Heart J"},{"key":"R39-20260204","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0140-6736(13)61170-8","article-title":"Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): A prospective multicentre registry study","volume":"382","author":"Stone","year":"2013","journal-title":"Lancet"},{"key":"R40-20260204","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.amjcard.2018.11.026","article-title":"Impact of point-of-care platelet function testing among patients with and without acute coronary syndromes undergoing percutaneous coronary intervention with drug-eluting stents (from the ADAPT-DES Study)","volume":"123","author":"Rinaldi","year":"2019","journal-title":"Am J Cardiol"},{"key":"R41-20260204","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ahj.2011.07.026","article-title":"Prasugrel overcomes high on-clopidogrel platelet reactivity in chronic coronary artery disease patients more effectively than high dose (150 mg) clopidogrel","volume":"162","author":"Alexopoulos","year":"2011","journal-title":"Am Heart J"},{"key":"R42-20260204","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1160\/TH12-06-0378","article-title":"Decrease in high on-treatment platelet reactivity (HTPR) prevalence on switching from clopidogrel to prasugrel: Insights from the switching anti-platelet (SWAP) study","volume":"109","author":"Saucedo","year":"2013","journal-title":"Thromb Haemost"},{"key":"R43-20260204","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ahj.2010.11.025","article-title":"The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: Combined analysis of the ONSET\/OFFSET and RESPOND studies","volume":"162","author":"Bliden","year":"2011","journal-title":"Am Heart J."},{"key":"R44-20260204","doi-asserted-by":"crossref","first-page":"13789","DOI":"10.1038\/srep13789","article-title":"Ticagrelor overcomes high platelet reactivity in patients with acute myocardial infarction or coronary artery in-stent restenosis: A randomized controlled trial","volume":"5","author":"Li","year":"2015","journal-title":"Sci Rep"},{"key":"R45-20260204","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jacc.2012.03.050","article-title":"Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: A pharmacodynamic study","volume":"60","author":"Alexopoulos","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"R46-20260204","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1160\/TH14-02-0119","article-title":"Ticagrelor vs prasugrel one-month maintenance therapy: Impact on platelet reactivity and bleeding events","volume":"112","author":"Alexopoulos","year":"2014","journal-title":"Thromb Haemost"},{"key":"R47-20260204","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11239-014-1119-9","article-title":"Comparison of platelet inhibition by prasugrel versus ticagrelor over time in patients with acute myocardial infarction","volume":"39","author":"Perl","year":"2015","journal-title":"J Thromb Thrombolysis"},{"key":"R48-20260204","doi-asserted-by":"crossref","first-page":"570","DOI":"10.3109\/09537104.2014.959914","article-title":"Comparison of platelet reactivity following prasugrel and ticagrelor loading dose in ST-segment elevation myocardial infarction patients: The COMPASSION study","volume":"26","author":"Laine","year":"2015","journal-title":"Platelets"},{"key":"R49-20260204","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.ijcard.2014.04.208","article-title":"Switching patients from clopidogrel to novel P2Y12 receptor inhibitors in acute coronary syndrome: Comparative effects of prasugrel and ticagrelor on platelet reactivity","volume":"174","author":"Lhermusier","year":"2014","journal-title":"Int J Cardiol"},{"key":"R50-20260204","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.2337\/dc12-2510","article-title":"Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with diabetes","volume":"36","author":"Alexopoulos","year":"2013","journal-title":"Diabetes Care"},{"key":"R51-20260204","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1160\/TH13-05-0384","article-title":"Ticagrelor versus prasugrel in diabetic patients with an acute coronary syndrome. A pharmacodynamic randomised study","volume":"111","author":"Laine","year":"2014","journal-title":"Thromb Haemost"},{"key":"R52-20260204","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12933-015-0232-1","article-title":"Diabetes mellitus and platelet reactivity in patients under prasugrel or ticagrelor treatment: An observational study","volume":"14","author":"Alexopoulos","year":"2015","journal-title":"Cardiovasc Diabetol"},{"key":"R53-20260204","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/jth.12907","article-title":"High on-treatment platelet reactivity with ticagrelor versus prasugrel: A systematic review and meta-analysis","volume":"13","author":"Lemesle","year":"2015","journal-title":"J Thromb Haemost"},{"key":"R54-20260204","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/MCA.0000000000000541","article-title":"Effect of ticagrelor versus prasugrel on platelet reactivity: A meta-analysis","volume":"28","author":"Zhang","year":"2017","journal-title":"Coron Artery Dis"},{"key":"R55-20260204","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/jth.12907","article-title":"High on-treatment platelet reactivity with ticagrelor versus prasugrel: A systematic review and meta-analysis","volume":"13","author":"Lemesle","year":"2015","journal-title":"J Thromb Haemost"},{"key":"R56-20260204","doi-asserted-by":"crossref","first-page":"905607","DOI":"10.3389\/fcvm.2022.905607","article-title":"Impact of prasugrel and ticagrelor on platelet reactivity in patients with acute coronary syndrome: A meta-analysis","volume":"9","author":"Dai","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"R57-20260204","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.acvd.2015.04.004","article-title":"Platelet effect of prasugrel and ticagrelor in patients with ST-segment elevation myocardial infarction","volume":"108","author":"Kerneis","year":"2015","journal-title":"Arch Cardiovasc Dis"},{"key":"R58-20260204","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.ijcard.2014.07.019","article-title":"Ticagrelor effectiveness overestimated by VASP index: Platelet inhibition by ticagrelor versus prasugrel in acute coronary syndrome patients according to platelet function tests","volume":"176","author":"Dillinger","year":"2014","journal-title":"Int J Cardiol"},{"key":"R59-20260204","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.jcin.2016.02.039","article-title":"Pharmacodynamic effects of switching from prasugrel to ticagrelor: Results of the prospective, randomized SWAP-3 study","volume":"9","author":"Franchi","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"R60-20260204","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1538-7836.2009.03709.x","article-title":"Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement","volume":"8","author":"Sibbing","year":"2010","journal-title":"J Thromb Haemost"},{"key":"R61-20260204","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.jcin.2013.04.009","article-title":"Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: The POBA study (predictor of bleedings with antiplatelet drugs)","volume":"6","author":"Cuisset","year":"2013","journal-title":"JACC Cardiovasc Interv"},{"key":"R62-20260204","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1111\/j.1538-7836.2012.04875.x","article-title":"Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel","volume":"10","author":"Bonello","year":"2012","journal-title":"J Thromb Haemost"},{"key":"R63-20260204","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ijcard.2012.09.214","article-title":"Platelet reactivity in diabetic patients undergoing coronary stenting for acute coronary syndrome treated with clopidogrel loading dose followed by prasugrel maintenance therapy","volume":"168","author":"Cuisset","year":"2013","journal-title":"Int J Cardiol"},{"key":"R64-20260204","doi-asserted-by":"crossref","first-page":"eAO7001","DOI":"10.31744\/einstein_journal\/2022AO7001","article-title":"Low platelet reactivity in patients with myocardial infarction treated with aspirin plus ticagrelor","volume":"20","author":"Costa","year":"2022","journal-title":"Einstein (S\u00e3o Paulo)"},{"key":"R65-20260204","doi-asserted-by":"crossref","first-page":"6246","DOI":"10.3390\/jcm11216246","article-title":"Escalation and de-escalation of antiplatelet therapy after acute coronary syndrome or PCI: Available evidence and implications for practice","volume":"11","author":"Gragnano","year":"2022","journal-title":"J Clin Med"},{"key":"R66-20260204","doi-asserted-by":"crossref","first-page":"e026482","DOI":"10.1161\/JAHA.122.026482","article-title":"On-treatment platelet reactivity and ischemic outcomes in patients with diabetes mellitus: Two-year results from ADAPT-DES","volume":"12","author":"Shahim","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"R67-20260204","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/eurheartj\/ehab836","article-title":"Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: A network meta-analysis of 61 898 patients from 15 randomized trials","volume":"43","author":"Galli","year":"2022","journal-title":"Eur Heart J"},{"key":"R68-20260204","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jcin.2020.01.226","article-title":"Derivation, validation, and prognostic utility of a prediction rule for nonresponse to clopidogrel: The ABCD-GENE score","volume":"13","author":"Angiolillo","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"key":"R69-20260204","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ijcard.2020.11.022","article-title":"Validation of the ABCD-GENE score to identify high platelet reactivity in east Asian patients undergoing percutaneous coronary intervention","volume":"327","author":"Saito","year":"2021","journal-title":"Int J Cardiol"},{"key":"R70-20260204","doi-asserted-by":"crossref","first-page":"e024156","DOI":"10.1161\/JAHA.121.024156","article-title":"ABCD-GENE score and clinical outcomes following percutaneous coronary intervention: Insights from the TAILOR-PCI trial","volume":"11","author":"Capodanno","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"R71-20260204","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1080\/AC.70.5.3110511","article-title":"The STIB score: A simple clinical test to predict clopidogrel resistance","volume":"70","author":"Legrand","year":"2015","journal-title":"Acta Cardiol"},{"key":"R72-20260204","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/ehjqcco\/qcx041","article-title":"Risk scoring to guide antiplatelet therapy post-percutaneous coronary intervention for acute coronary syndrome results in improved clinical outcomes","volume":"4","author":"Antoniou","year":"2018","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"R73-20260204","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0140-6736(17)32155-4","article-title":"Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): A randomised, open-label, multicentre trial","volume":"390","author":"Sibbing","year":"2017","journal-title":"Lancet"},{"key":"R74-20260204","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1093\/eurheartj\/ehx175","article-title":"Benefit of switching dual antiplatelet therapy after acute coronary syndrome: The TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study","volume":"38","author":"Cuisset","year":"2017","journal-title":"Eur Heart J"},{"key":"R75-20260204","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/j.jacc.2011.08.007","article-title":"2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention","volume":"58","author":"Levine","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"R76-20260204","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","article-title":"2014 AHA\/ACC guideline for the management of patients with non\u2013ST-elevation acute coronary syndromes","volume":"64","author":"Amsterdam","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R77-20260204","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.4244\/EIJY19M01_01","article-title":"2018 ESC\/EACTS Guidelines on myocardial revascularization","volume":"14","author":"Neumann","year":"2019","journal-title":"EuroIntervention"},{"key":"R78-20260204","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet","year":"2021","journal-title":"Eur Heart J"},{"key":"R79-20260204","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jjcc.2018.10.005","article-title":"Prevalence and predictors of high-on treatment platelet reactivity during prasugrel treatment in patients with acute coronary syndrome undergoing stent implantation","volume":"73","author":"Verdoia","year":"2019","journal-title":"J Cardiol"},{"key":"R80-20260204","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3390\/jcm12031149","article-title":"Ticagrelor resistance in cardiovascular disease and ischemic stroke","volume":"12","author":"He","year":"2023","journal-title":"J Clin Med"},{"key":"R81-20260204","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1038\/s41598-019-40628-0","article-title":"Determinants of high platelet reactivity in patients with acute coronary syndromes treated with ticagrelor","volume":"9","author":"Adamski","year":"2019","journal-title":"Sci Rep"},{"key":"R82-20260204","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/eurheartj\/ehv547","article-title":"Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: The randomized, double-blind, placebo-controlled IMPRESSION trial","volume":"37","author":"Kubica","year":"2016","journal-title":"Eur Heart J"}],"container-title":["Journal of Family Medicine and Primary Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_1473_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:35:20Z","timestamp":1787067320000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_1473_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":81,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_1473_23","relation":{},"ISSN":["2249-4863","2278-7135"],"issn-type":[{"value":"2249-4863","type":"print"},{"value":"2278-7135","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"2023-09-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-22","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}